Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Truist Securities Upgrades Evolent Health to Buy, Raises Price Target to $33

Author: Benzinga Newsdesk | August 09, 2024 05:50am
Truist Securities analyst Jailendra Singh upgrades Evolent Health (NYSE:EVH) from Hold to Buy and raises the price target from $28 to $33.

Posted In: EVH

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist